NMRA
Neumora Therapeutics, Inc.
NASDAQ: NMRA · HEALTHCARE · BIOTECHNOLOGY
$2.25
+0.00% today
Updated 2026-04-29
Market cap
$405.57M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.45
Dividend yield
—
52W range
$1 – $4
Volume
1.1M
Neumora Therapeutics, Inc. (NMRA) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
8 of 8
Last 8 quarters
Avg EPS surprise
+20.8%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+5.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-3.0%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-3.7%
2026-03-11
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-11 | $-0.35 | +25.5% | $3.26 | $3.14 | -3.7% |
| 2025-11-06 | $-0.35 | +22.2% | $2.62 | $2.56 | -2.3% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.47 | $-0.35 | +25.5% | — | — |
| 2025-09-30 | $-0.45 | $-0.35 | +22.2% | — | — |
| 2025-06-30 | $-0.45 | $-0.33 | +26.7% | — | — |
| 2025-03-31 | $-0.46 | $-0.42 | +8.7% | — | — |
| 2024-12-31 | $-0.62 | $-0.37 | +40.3% | — | — |
| 2024-09-30 | $-0.65 | $-0.45 | +30.8% | — | — |
| 2024-06-30 | $-0.68 | $-0.37 | +45.6% | — | — |
| 2024-03-31 | $-0.34 | $-0.34 | +0.0% | — | — |
| 2023-12-31 | $-0.55 | $-0.71 | -29.1% | — | — |
| 2023-09-30 | $-0.36 | $-1.14 | -216.7% | — | — |
| 2023-06-30 | $0.00 | $-0.28 | — | — | — |
Frequently asked questions
Has Neumora Therapeutics, Inc. beaten earnings estimates?
Neumora Therapeutics, Inc. has beaten Wall Street EPS estimates in 8 of its last 8 quarterly reports, with an average EPS surprise of +20.8% over the last 4 quarters.
How does NMRA stock react to earnings?
NMRA stock has moved an average of -3.0% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.